Search results
Showing 961 to 975 of 1516 results for patients and public
Awaiting development Reference number: GID-TA11659 Expected publication date: 13 May 2027
Awaiting development Reference number: GID-TA11624 Expected publication date: TBC
Fluorouracil chemotherapy: The My5‑FU assay for guiding dose adjustment (HTG360)
Evidence-based recommendations on the My5-FU assay for measuring levels of 5-flurouracil (5-FU) in patients having chemotherapy, to help guide changes to the dose of 5-FU.
Evidence-based recommendations on trastuzumab emtansine (Kadcyla) for human epidermal growth factor receptor 2 (HER2)-positive, unresectable, locally advanced or metastatic breast cancer in adults who have had trastuzumab and a taxane.
This guideline covers general principles for prescribing and managing withdrawal from opioids, benzodiazepines, gabapentinoids, Z-drugs and antidepressants in primary and secondary care.
People can comment on our guidance at specific stages in its development.
People can comment on our guidance at specific stages in its development.
Masitinib with riluzole for treating amyotrophic lateral sclerosis [ID6257]
In development Reference number: GID-TA11071 Expected publication date: TBC
Duvelisib for treating relapsed or refractory peripheral T-cell lymphoma [ID5076]
Awaiting development Reference number: GID-TA10961 Expected publication date: TBC
In development Reference number: GID-TA11422 Expected publication date: TBC
In development Reference number: GID-TA11584 Expected publication date: 08 December 2027
Awaiting development Reference number: GID-TA11538 Expected publication date: TBC
In development Reference number: GID-TA11130 Expected publication date: TBC
We are listening to your views on this Technology appraisal guidance. Comments close 18 February 2026.
In development Reference number: GID-TA11694 Expected publication date: TBC